
Table of Contents

Section I: General Information

Chapter 1	FDA and Related Regulatory Agencies.....1 <i>By Mitchell S. Berger, MPH, JD, RAC and Barry A. Berger, JD, MBA</i>
Chapter 2	History of Food, Drug and Cosmetic Laws41 <i>Updated by Meredith Brown-Tuttle, RAC, FRAPS</i>
Chapter 3	Overview of Drug, Biologic, Device, Combination Product or Food Regulatory Pathways53 <i>Updated by Michael R. Hamrell, PhD, RQAP-GCP, CCRA, FACRP, RAC, FRAPS</i>
Chapter 4	FDA Communications and Meetings.....85 <i>Updated by Kell Cannon, MBA and Jamie Page, MBA</i>
Chapter 5	Preparing for FDA Advisory Committee Meetings97 <i>Updated by Jim DiBiasi and Virginia Cox, JD</i>
Chapter 6	Good Laboratory Practice Regulations107 <i>Updated by Kurt Stabl and Jennifer G. Brown, PhD, RAC</i>
Chapter 7	Clinical Trials: GCPs, Regulations and Compliance for Drugs, Biologics and Medical Devices119 <i>Updated by Monique Carter, MS, RAC and Samantha Zappia, MS, RAC</i>
Chapter 8	Current Good Manufacturing Practices and Quality System Design157 <i>Updated by Joscelyn Bowersock, MS-RA, and Richard Vincins, CQP, MCQL, CBA, CQA, RAC</i>
Chapter 9	FDA User Fees173 <i>Updated by Allison C. Komiyama, PhD, RAC and Michelle J. Rubin-Onur, PhD</i>
Chapter 10	Regulatory Strategy179 <i>By Karen Fan, MSc, RAC, PEng and Robert Falcone, PhD</i>
Chapter 11	Master Protocol.....187 <i>By Jessica Foley, MS, RAC and Lauren Neighbours, PhD, RAC</i>
Chapter 12	Traceability and Supply Chain195 <i>Updated by Jyoti Chauhan, MS, RAC and Helen Simons, MEng</i>
Chapter 13	Healthcare Fraud and Abuse Compliance.....213 <i>Updated by Sam Rajkumar, MS, RN and Priya Mannan, JD, LLM</i>

Section II: Drugs

Chapter 14	Prescription Product Drug Submissions223 <i>By Shyamala Jayaraman, PhD, Lean Six Sigma Black Belt and Glen D. Park, PharmD, MSJ</i>
------------	--

Chapter 15	Postapproval Submissions and Compliance: Prescription Drugs and Biologics	245
	<i>Updated by Emily Rapp, RAC and Dar Rosario, MBA, RAC</i>	
Chapter 16	Generic Drug Submissions.....	265
	<i>Updated by Amrita Ghosh, RAC and Sharry Arora, MPharm</i>	
Chapter 17	Patents and Exclusivity.....	277
	<i>Updated by Kurt R. Karst, JD</i>	
Chapter 18	Over-the-Counter (Nonprescription) Drug Products	291
	<i>Updated by Valerie Ramsey, DRSc, MS, RAC</i>	
Chapter 19	Prescription Drug Labeling, Advertising and Promotion	301
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 20	Pharmacovigilance and Risk Management.....	315
	<i>Updated by Stacy Woeppel, MBA and Robert Falcone, PhD</i>	

Section III: Medical Devices

Chapter 21	Medical Device Submissions	329
	<i>Updated by Maria Connolly, MPharm and Thomas McNamara, MSE, RAC</i>	
Chapter 22	Medical Device Compliance and Postmarketing Activities	357
	<i>Updated by Ryan Burke, RAC and Elizabeth Goldstein, RAC</i>	
Chapter 23	In Vitro Diagnostics Submissions and Compliance	369
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 24	Advertising, Promotion and Labeling for Medical Devices and In Vitro Diagnostics (IVDs).....	379
	<i>Updated by Carol M. Cooper, MS, IM(ASCP), RM(AAM), RAC</i>	

Section IV: Biologics

Chapter 25	Biologics Submissions	389
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 26	Biologics Compliance.....	417
	<i>Updated by Anne Marie Woodland, MS, RAC</i>	
Chapter 27	Biosimilars	429
	<i>Updated by Nathalie Innocent, MS, RAC and Jennifer Wilhelm, MSc, MBA, RAC</i>	
Chapter 28	Biologics Labeling, Advertising and Promotion	451
	<i>By Kathrin Schalper, PhD, RAC</i>	
Chapter 29	Blood and Blood Products	463
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC and Natalia Rimmel, PhD, MSRA, RAC</i>	
Chapter 30	Regulating Cell & Gene Therapies, Genetically Modified Cells and Devices in Regenerative Medicine.....	473
	<i>Updated by Angela N. Johnson, MSE, PMP, RAC</i>	

Section V: Foods

Chapter 31	Food Products.....	509
	<i>By Letaasha B. Gorham, MBA</i>	
Chapter 32	Dietary Supplements and Homeopathic Products	527
	<i>Updated by Letaasha B. Gorham, MBA</i>	

Chapter 33	Medical Foods.....	551
	<i>Updated by Carlos Alexandre Biella, MBA</i>	

Section VI: Other Product Classifications

Chapter 34	Combination Products.....	561
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 35	Products for Small Patient Populations.....	573
	<i>Updated by Todd J. Banks, PharmD, RPh and Celeste A. Morris, PhD, RAC</i>	
Chapter 36	Human Cell and Tissue Products.....	587
	<i>Updated by Lauren Neighbours, PhD, RAC, and Jessica Foley, MS, RAC</i>	
Chapter 37	Pediatric Drug and Device Development.....	599
	<i>By Lynne Georgopoulos, RN, MSHS, RAC and Daniela Drago, PhD, FTOPRA, RAC</i>	

Section VII: Inspection and Enforcement

Chapter 38	FDA Inspection and Enforcement.....	615
	<i>Updated by Robert Rogers, MS, RAC</i>	

Section VIII: Resources

Chapter 39	Regulatory Information Resources in Review.....	625
	<i>By Elizabeth Goldstein, RAC and Dinar Suleman, RAC</i>	

Appendices

Comparative Matrix of Regulations Across Product Lines.....	647
Glossary of Terms.....	679
Index of Laws and Guidances.....	703
Index by Subject.....	711

Figures

Figure 1-1.	Food and Drug Administration Organizational Chart.....	7
Figure 3-1.	Decision Tree for Drug and Device Development and Approval When FDA Premarket Review is Required.....	61
Figure 3-2.	CTD Organization.....	67
Figure 4-1.	NDA and BLA Submissions.....	88
Figure 5-1.	Major Milestone Timeline.....	104
Figure 5-2.	Project Management Chart.....	105
Figure 7-1.	Types of Pharmaceutical and Biologic Clinical Trials and Typical Pathway.....	128
Figure 7-2.	Types of Medical Device Clinical Trials and Typical Pathway.....	141
Figure 8-1.	Quality System Documentation Elements.....	159
Figure 8-2.	Design Control “V” Model Process Flow.....	160
Figure 12-1.	Supply Chain Entities.....	198
Figure 12-2.	Timelines for Implementing Key Plan Elements.....	201
Figure 12-3.	Timelines for Implementing Key Plan Elements.....	202
Figure 12-4.	Decision Tree to Determine Whether a Drug Package or Case Needs a Product Identifier.....	204
Figure 12-5.	Convenience Kit Example.....	210
Figure 14-1.	FDA IND Review Process.....	229
Figure 14-2.	Diagram of the ICH Common Technical Document (CTD).....	235
Figure 14-3.	Timeline and Product Review Clock.....	238
Figure 15-1.	Summary of Reporting Categories for Postapproval Changes.....	250
Figure 15-2.	Example of a CMC Index.....	256
Figure 18-1.	Example of an OTC Drug Facts Label.....	298
Figure 27-1.	Number of Biosimilar INDs Received by CDER by Fiscal Year.....	433
Figure 27-2.	Number of Biosimilar Type 1–4 Meetings Held by CDER by Fiscal Year.....	433
Figure 30-1.	Overview of Regenerative Medicine Regulatory Framework.....	476

Figure 30-2.	Framework for Assessing Gene Therapy-Related Delayed Adverse Event Risks	502
Figure 36-1.	Process Flow for 21 CFR 1271 HCT/P Criteria	590
Figure 37-1.	Timeline of Key US Pediatric Development Initiatives	602
Figure 37-2.	Building the Pediatric Development Strategy	607
Figure 37-3.	Pediatric Study Planning Extrapolation Decision Tree	609
Figure 37-4.	Schematic of iPSP Submission and Review Process	610

Tables

Table 2-1.	Electronic Resources for US Laws and Regulations	43
Table 2-2.	Other Laws, Regulations and Guidelines.....	50
Table 3-1.	Title 21 CFR Parts.....	60
Table 3-2.	Key Questions in a Drug Development Program	63
Table 3-3.	IND Safety Reporting Timeframes.....	69
Table 3-4.	Summary of Device Classification System	76
Table 4-1.	Description of FDA Product Application Meetings and Associated Timelines.....	90
Table 5-1.	Current FDA Advisory Committees.....	100
Table 5-1.	Current FDA Advisory Committees (cont'd.).....	101
Table 5-2.	Advisory Committee Meetings (1 January 2018–31 December 2018).....	102
Table 7-1.	Significant Legislation Relevant to Clinical Trials in the US	122
Table 7-2.	Comparison of 21 CFR and ISO-GCP Requirements for Protocol Deviations in Medical Device Clinical Trials.....	126
Table 7-3.	Comparison of 21 CFR and ISO GCP Requirements for Investigator Responsibilities in Medical Device Clinical Trials	147
Table 7-4.	Comparison of 21 CFR and ISO-GCP Requirements for Recordkeeping in Medical Device Clinical Trials.....	148
Table 7-5.	Comparison of 21 CFR and ISO-GCP Requirements for Device Accountability in Medical Device Clinical Trials	149
Table 10-1.	Target Product Profile (TPP) Summarizing Label Concepts	180
Table 10-2.	Key Databases for US Regulatory Information (Free of Charge).....	181
Table 10-3.	Regulatory Key Questions During Development (Pharmaceuticals)	182
Table 12-1.	Terms and Definitions.....	197
Table 12-2.	Transaction Terms and Definitionsa	198
Table 12-3.	DSCSA Stakeholder Definitions and Key Terminology	199
Table 12-4.	Timelines for Implementing Key Plan Elements.....	200
Table 12-5.	Public Meetings Under DSCSA	206
Table 13-1.	State Laws on Manufacturer Interaction With Healthcare Providers.....	217
Table 17-1.	180-Day Exclusivity Forfeiture Snapshot.....	285
Table 17-2.	Differences Among Applications Submitted and Approved Under FD&C Act Section 505	286
Table 18-1.	OTC Monograph Therapeutic Category Subtopics Evaluated as Part of the OTC Review Process	294
Table 18-2.	Acne Drug Products: Benzoyl Peroxide	295
Table 18-3.	NDA vs. OTC Drug Monograph.....	296
Table 19-1.	PLR Format, Associated Regulations and Guidance Documents	306
Table 20-1.	Safety Reporting Requirements for Drugs/Biologics.....	324
Table 20-2.	Safety Reporting Requirements for Medical Devices	325
Table 21-1.	Device Classification Summary of Requirements.....	333
Table 21-2.	Typical Data Requirements Based on Device Class.....	335
Table 21-3.	Typical Device Studies Covered Under the IDE Regulation	336
Table 22-1.	Domestic Establishments	359
Table 22-2.	Foreign Establishments	360
Table 22-3.	Annual Registration Process	366
Table 25-1.	Key Milestones in the Regulatory Oversight of Biologics.....	393
Table 25-2.	Applications Regulated by PHS Act	394
Table 25-3.	Applications Regulated by the FD&C Act	395
Table 25-4.	Biologics Controlled by CDER and CBER	396
Table 25-5.	Submissions With Specific Regulatory Mandated Timelines (e.g., SPAs) or FDA Established Timelines (e.g., Reviews of Proposed Pediatric Study Requests).....	398
Table 25-6.	Safety-Related Submissions	400
Table 25-7.	IND Drug Development Submissions	402
Table 25-8.	Other Submission Types.....	404
Table 25-9.	Key CMC Guidance for Biological Product Development	406
Table 25-10.	NDA/BLA Standard and Priority Review Process (PDUFA VI)	410
Table 27-1.	BsUFA Fees Financial Year 2019a.....	432

Table 27-2.	Meetings Between FDA and Biosimilar Biological Product Sponsors	434
Table 27-3.	Comparison of Development Programs Between Chemical Drugs and Biological Products.....	438
Table 27-4.	FDA-Approved Biosimilars	443
Table 30-1.	Current Definitions of Regenerative Medicine and their Regulatory Basis.....	477
Table 30-2.	General Medicinal Product Classes in Regenerative Medical Products.....	478
Table 30-3.	Requirements for Section 361 HCT/Ps.....	480
Table 30-4.	Public Information on Approved and Developing Regenerative Cell and Gene Therapies	482
Table 30-5.	Key Terms for Characterizing Cell Therapies.....	484
Table 30-6.	Disease-Specific Cell Therapy Guidance Documents.....	486
Table 30-7.	Key Gene Therapy Guidance Documents.....	487
Table 30-8.	Vectors in Gene Therapy	487
Table 30-9.	Disease-Specific Gene Therapy Guidance Documents	488
Table 30-10.	Summary of Specific IND Information for Cell Populations for Therapeutic Use.....	488
Table 30-11.	Current Regulatory Terminology for Devices Used in Regenerative Medicine	494
Table 30-12.	General Types of Devices for Use in Regenerative Medicine Combination Products.....	495
Table 30-13.	Regenerative Device PMA/HDE Approvals	496
Table 30-14.	Summary of Specific IDE Information for Regenerative Devices.....	496
Table 30-15.	Regenerative Tissue Engineering Devices Currently in Development	497
Table 30-16.	FDA Clinical Trial Design and Endpoint Guidance for Cell and Gene Products	499
Table 30-17.	Features of Cell and Gene Therapy Products That Influence Clinical Trial Design.....	500
Table 30-18.	Design of Early Phase Clinical Trials for Gene and Cell Therapy Products	501
Table 30-19.	Integration Properties of Current Commonly Used Gene Therapy Vectors in Clinical Trials	503
Table 34-1.	Unique Postmarket Safety Reporting Provisions for Combination Products	568
Table 36-1.	21 CFR 1271	589
Table 36-2.	Overview of the Core CGTP Requirements (21 CFR 1271, Subpart D).....	592
Table 36-3.	FDA Regulation of Minimally Manipulated Cord Blood Products.....	594
Table 37-1.	Pediatric Subpopulations for iPSP	605
Table 37-2.	ICH E1 Pediatric Age Classifications	606
Table 37-3.	Quick Reference Guide to Complying with PREA and Submission of an iPSP	608
Table 37-4.	Content of the Initial Pediatric Study Plan.....	611
Table 37-5.	FDA Subpopulation Description	612
Table 38-1.	FDA Enforcement Actions.....	620
Table 39-1.	Agencies, Organizations, Institutes, Centers and Offices Associated with Healthcare Product Regulation	628
Table 39-2.	Databases for Healthcare Product Regulatory-Related Intelligence.....	630
Table 39-3.	Publisher Resources.....	638
Table 39-4.	Societies, Trade Associations, Advocacy Groups and Associations Providing Learning Resources	643